Five-Year Milestone: Social media users marked Hims & Hers Health's fifth anniversary as a public company with notable enthusiasm, highlighting the stock's ring of the opening bell and substantial long-term expansion. Revenue has surged dramatically over the period, drawing attention to the company's scaled operations in telehealth services.
Growth and Expansion: Discussions emphasized the firm's progress in women's health through the Hers brand, projecting toward a billion-dollar revenue segment by year-end. Analysts on social media noted potential partnerships and product line extensions, including weight management offerings, as drivers of sustained momentum amid broader industry shifts.
Market Sentiment: Technical observers pointed to bullish chart patterns with targets around higher levels, while some voiced caution over future competition in key drug categories. Overall, the tone reflected optimism around subscriber gains and operational scaling.
Note: This discussion summary was generated from an AI condensation of post data.
Hims & Hers Health Insider Trading Activity
Hims & Hers Health insiders have traded $HIMS stock on the open market 20 times in the past 6 months. Of those trades, 1 have been purchases and 19 have been sales.
Here’s a breakdown of recent trading of $HIMS stock by insiders over the last 6 months:
- OLUYEMI OKUPE (Chief Financial Officer) has made 0 purchases and 9 sales selling 128,237 shares for an estimated $3,642,047.
- MICHAEL CHI (Chief Operating Officer) has made 0 purchases and 2 sales selling 111,316 shares for an estimated $2,843,915.
- DAVID B WELLS purchased 48,400 shares for an estimated $1,172,974
- MOHAMED ELSHENAWY (CTO) sold 30,040 shares for an estimated $946,260
- PATRICK HARRISON CARROLL (Chief Medical Officer) sold 23,726 shares for an estimated $830,410
- IRENE BECKLUND (PAO) has made 0 purchases and 3 sales selling 17,592 shares for an estimated $507,029.
- SOLEIL BOUGHTON (Chief Legal Officer) has made 0 purchases and 3 sales selling 18,926 shares for an estimated $473,439.
To track insider transactions, check out Quiver Quantitative's insider trading dashboard. You can access data on insider stock transactions through the Quiver Quantitative API insider transaction endpoint.
Hims & Hers Health Revenue
Hims & Hers Health had revenues of $753.2M in Q2 2026. This is an increase of 38.25% from the same period in the prior year.
You can track HIMS financials on Quiver Quantitative's HIMS stock page.
You can access data on HIMS stock through the Quiver Quantitative API.
Hims & Hers Health Hedge Fund Activity
We have seen 316 institutional investors add shares of Hims & Hers Health stock to their portfolio, and 286 decrease their positions in their most recent quarter.
Here are some of the largest recent moves:
- CAPITAL WORLD INVESTORS removed 14,322,912 shares (-100.0%) from their portfolio in Q1 2026, for an estimated $297,343,653
- DEFIANCE ETFS, LLC removed 7,424,258 shares (-100.0%) from their portfolio in Q2 2026, for an estimated $257,399,024
- DIVISADERO STREET CAPITAL MANAGEMENT, LP added 5,539,672 shares (+1179.1%) to their portfolio in Q2 2026, for an estimated $192,060,428
- JPMORGAN CHASE & CO added 4,766,781 shares (+inf%) to their portfolio in Q2 2026, for an estimated $165,264,297
- FMR LLC added 4,230,022 shares (+4535.2%) to their portfolio in Q2 2026, for an estimated $146,654,862
- MARSHALL WACE, LLP added 3,493,540 shares (+482.4%) to their portfolio in Q2 2026, for an estimated $121,121,031
- FARALLON CAPITAL MANAGEMENT LLC removed 3,376,986 shares (-99.7%) from their portfolio in Q1 2026, for an estimated $70,106,229
To track hedge funds' stock portfolios, check out Quiver Quantitative's institutional holdings dashboard. You can access data on hedge funds moves and 13F filings through the Quiver Quantitative API 13F endpoint.
Hims & Hers Health Price Targets
Multiple analysts have issued price targets for $HIMS recently. We have seen 12 analysts offer price targets for $HIMS in the last 6 months, with a median target of $28.0.
Here are some recent targets:
- Allen Lutz from B of A Securities set a target price of $37.0 on 07/09/2026
- Maria Ripps from Canaccord Genuity set a target price of $40.0 on 07/01/2026
- Glen Santangelo from Barclays set a target price of $39.0 on 06/18/2026
- Jailendra Singh from Truist Securities set a target price of $23.0 on 05/22/2026
- Ryan MacDonald from Needham set a target price of $35.0 on 05/12/2026
- Cory Carpenter from JP Morgan set a target price of $33.0 on 05/12/2026
- Daniel Grosslight from Citigroup set a target price of $28.0 on 05/12/2026
This article is not financial advice. See Quiver Quantitative's disclaimers for more information. Note that there may be inaccuracies due to mistakes in ticker-mapping, and other anomalies.
